The peptide exhibits minimal to moderate side effects, has low oral bioavailability, and excellent subcutaneous bioavailability in mice
Considering greater effects of semaglutide on other medical outcomes (eg, weight loss) with increasing dose and treatment duration, higher doses would presumably yield greater effects on alcohol reduction
Research protocols typically use 20-80 mcg daily via subcutaneous injection, cycled 4 weeks on, 4 weeks off
To learn more benefits, contact us or schedule an appointment online
If you have been managing a chronic soft tissue issue, GI inflammation that standard approaches have not resolved, or post-surgical recovery that is progressing slower than expected, a BPC-157 consultation at our Doral clinic starts with a full clinical intake, not a generic protocol handed off without context
Early phase 2 data showed average weight loss of approximately 24 percent at 48 weeks, with the STEP UP trial demonstrating 20.7 percent average weight reduction with the higher dose formulation at 72 weeks